Nephros, Inc.
NEPHHealthcareNASDAQMedical Instruments & Supplies
Scan Results
Daily timeframeHeadquartered within the healthcare sector, Nephros, Inc. focuses on Medical Instruments & Supplies services and products. Nephros, Inc., a commercial-stage company, develops and sells water filtration solutions for medical and commercial applications in the United States. The $38.3M market capitalization puts NEPH squarely in micro-cap range for its industry. It offers ultrafiltration products that are used in dialysis centers for the removal of biological contaminants from water and bicarbonate concentrate; and in hospitals for the prevention of infection from waterborne pathogens, such as legionella and pseudomonas, as well as in foodservice and hospitality, and other healthcare facilities.
Market Cap
$38.3M
Beta
1.64
P/E (TTM)
23.53
P/E (Fwd)
16.81
EPS (TTM)
$0.15
EPS (Fwd)
$0.21
ROE
16.1%
ROA
7.3%
Cash
$4.7M
Total Debt
$872,000
Free CF
-$1.4M
52W Change
-34.9%
Annual Financials
Cash vs Debt
Where NEPH stands vs its 150-day and 200-day moving averages
As of the October 20, 2026 close, NEPH finished 3.08% above its 150-day moving average ($3.57) and 1.34% below its 200-day moving average ($3.73). This snapshot is end-of-day data shown with a five-trading-day delay on the free plan; Premium members see readings from the latest close.
Is NEPH overbought or oversold?
At the October 20, 2026 close, NEPH's RSI(14) was 43.8, in neutral territory (between 30 and 70). The MACD histogram was positive, so short-term momentum leaned bullish at that close. These readings are historical, refresh daily after market close, and are not investment advice.
The balance sheet looks solid with $4.7M in cash comfortably exceeding the $872K debt load. A net cash position generally provides financial flexibility during uncertain economic periods. Free cash flow is running at -$1.4M, which bears watching. Negative free cash flow can be acceptable during heavy investment periods but needs to improve over time. Return on equity stands at 16.1%, which is strong for the sector. ROE measures how effectively a company uses shareholder capital to generate profits. An ROA of 7.3% suggests reasonable efficiency in deploying the company's asset base. Revenue has grown from $10.0M (2022) to $18.8M (2025), reflecting a 88% increase over the period.
With a beta above 1.5, NEPH tends to amplify broader market moves — both up and down. This higher volatility means larger price swings are common. With cash comfortably exceeding debt, NEPH has financial flexibility that may help navigate uncertain periods. The company is burning cash at the operating level, which is not unusual for growth-phase companies but adds risk if it persists. Understanding these risk dimensions helps frame what to watch going forward as conditions evolve for Nephros, Inc. and its sector.